Deutsche Bank AG Has $168,000 Stock Position in Agenus Inc. (NASDAQ:AGEN)

Deutsche Bank AG increased its position in shares of Agenus Inc. (NASDAQ:AGEN) by 538.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 61,144 shares of the biotechnology company’s stock after buying an additional 51,566 shares during the quarter. Deutsche Bank AG owned about 0.26% of Agenus worth $168,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Barclays PLC raised its stake in Agenus by 17.7% during the 4th quarter. Barclays PLC now owns 32,737 shares of the biotechnology company’s stock worth $90,000 after buying an additional 4,924 shares during the period. Corton Capital Inc. acquired a new position in Agenus during the 4th quarter worth approximately $36,000. Virtu Financial LLC acquired a new position in Agenus during the 4th quarter worth approximately $51,000. Apollon Wealth Management LLC acquired a new position in Agenus during the 4th quarter worth approximately $55,000. Finally, Bank of Montreal Can acquired a new position in Agenus during the 4th quarter worth approximately $69,000. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Trading Up 20.4%

Shares of AGEN opened at $4.13 on Tuesday. The company has a market capitalization of $113.23 million, a price-to-earnings ratio of -0.37 and a beta of 1.48. The stock has a 50 day moving average of $2.67 and a 200 day moving average of $2.89. Agenus Inc. has a 12 month low of $1.38 and a 12 month high of $19.69.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.03) EPS for the quarter, beating analysts’ consensus estimates of ($1.61) by $0.58. The business had revenue of $24.07 million for the quarter, compared to analysts’ expectations of $26.38 million. As a group, equities research analysts predict that Agenus Inc. will post -12.55 earnings per share for the current year.

Analysts Set New Price Targets

AGEN has been the topic of a number of research reports. Wall Street Zen raised Agenus from a “strong sell” rating to a “hold” rating in a research note on Thursday, May 22nd. B. Riley reissued a “buy” rating on shares of Agenus in a research note on Monday, April 21st. HC Wainwright reissued a “neutral” rating on shares of Agenus in a research note on Tuesday, May 13th. Finally, Robert W. Baird increased their price objective on Agenus from $3.00 to $4.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 13th. Six research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat, Agenus presently has a consensus rating of “Hold” and a consensus target price of $9.00.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.